Clinical Trial Search

Primary: Percentage of Participants With Pathological Complete Response (pCR) — 13 percentage of participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment — 20; 40 Percentage of participants

Primary: Confirmed Overall Response Rate Per the RECIST 1.1 Criteria — 0 percentage of patients

Primary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months

Primary: Overall Survival (OS) — 13.73; 13.14 Months

Primary: Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 2.83; 2.07 Months — p=0.0114

Primary: 12-week Progression Free Rate — 68.29 percentage of participants

Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Response Rate (Per RECIST 1.1) — 1 Participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Progression Free Survival at 12 Weeks — 66; 57.2 percentage of particpants

Primary: Number of Participants Who Were Progression Free — 12 Participants

Primary: Progression-free Survival (PFS) — 8.18; 8.38; 7.16 Months — p=0.0956

Primary: 12-week Progression Free Survival (PFS) — 69.6; 36.8; 52.6 percentage of participants

Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001

Primary: The Objective Response Rate (ORR) Based on RECIST 1.1 — 6 Participants

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: The Average Percent Volume Reduction in the Lipoma. — 50 Percent Volume reduction (cc^3)

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Efficacy - Change in Lipomas Dimensions — -15.13; -15.92 percentage of change from baseline

Primary: Number of Participants With Adverse Events (AEs) — 12; 13; 14; 12 participants

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Part 2: Radiologic Progression-free Survival (PFS) — 18.7; 24.1 weeks — p== 0.6562

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Objective Tumor Response (Complete and Partial) — 2 Participants